TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16269047
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with triple-therapy (azathioprine, methylprednisolone, cyclosporine)
Study: 7011354
Drug: Combined infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined infusion of aminophylline and salbutamol
Study: 19452376
Drug: Rivastigmine 6
Normalized name: rivastigmine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 6 mg/day
Study: 14521803
Drug: Platinum/paclitaxel-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum/paclitaxel-based chemotherapy
Study: 8686816
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous propofol anaesthesia (median total dose of propofol 710 mg)
Study: 8686816
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous propofol anaesthesia
Study: 1839799
Drug: Concomitant antibiotic‐anti‐inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant antibiotic‐anti‐inflammatory therapy
Study: 6633131
Drug: Carbon dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon dioxide laser treatment
Study: 25007361
Drug: ABT 50
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT 50 mg
Study: 22687392
Drug: modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: modafinil 200 mg daily
Study: 19735903
Drug: Opioid rotation
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid rotation using equianalgesic dose tables
Study: 19735903
Drug: Starting dose
Normalized name: Austedo 6 MG Starting Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of new opioid based on relative potency
Study: 17623486
Drug: Milk supplemented
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplemented with 3 g CLA (cis-9, trans-11 and trans-10, cis-12)
Study: 15886218
Drug: Octreotide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (300 microg b.i.d.) added to diuretics (furosemide and spironolactone)
Study: 15886218
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of diuretics
Study: 15886218
Drug: Diuretics (furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (furosemide and spironolactone)
Study: 8587482
Drug: Albuterol (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (16 mg.d‐1)
Study: 8587482
Drug: Albuterol with
Normalized name: albuterol with CFC 90 mcg/inh inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol with resistance exercise
Study: 2676872
Drug: Bunazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin (1 to 3 mg t.i.d.)
Study: 2676872
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 to 40 mg t.i.d.)
Study: 367426
Drug: extra‐amniotic prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: extra‐amniotic prostaglandin E2 gel
Study: 367426
Drug: oral prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral prostaglandin E2
Study: 28550827
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (pantoprazol, amoxicillin, and clarithromycin 12/12 hours for 14 days)
Study: 28550827
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (pantoprazol 12/12 hours for 10 days, amoxicillin 12/12 hours for days 1-5, and clarithromycin plus metronidazol 12/12 hours during days 6-10)
Study: 26111333
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics (oral amoxicillin 50 mg/kg/day for 5 days)
Study: 23221573
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (FXCO) - 20.6 g ALA/d
Study: 23221573
Drug: High-oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-oleic acid canola oil (HOCO) - 2.4 g ALA/d
Study: 23221573
Drug: Western diet
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western diet (WD) - 1.3 g ALA/d
Study: 19796303
Drug: 25% H(2)O(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% H(2)O(2) gel with light enhancement
Study: 19796303
Drug: 25% H(2)O(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% H(2)O(2) gel alone
Study: 14703424
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tramadol
Study: 14703424
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tramadol plus 0.1 mg droperidol
Study: 1290441
Drug: Paracervical block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical block using 20 ml of 1% lignocaine
Study: 1290441
Drug: Uterosacral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral block using 2 ml of 2% lignocaine
Study: 27028981
Drug: Betahistine (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (48 mg/d)
Study: 22235353
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) in co-infected children with O. viverrini
Study: 22235353
Drug: Mebendazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (500 mg) in co-infected children with O. viverrini
Study: 19515110
Drug: PPI (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI (lansoprazole 15 mg/d)
Study: 19765430
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional therapies)
Study: 16078671
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sertraline daily for 12 weeks
Study: 16078671
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sertraline daily plus 50 mg sildenafil as needed for 12 weeks
Study: 11953346
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor omeprazole
Study: 24720340
Drug: Nurotron Venus
Normalized name: Zeltnera venusta whole flowering extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurotron Venus cochlear implants
Study: 16652049
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of antiretroviral medication
Study: 16652049
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antiretroviral therapy
Study: 8641639
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous immunoglobulins (IVIG) 300 mg/kg every 4 weeks for 6 months
Study: 8641639
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous immunoglobulins (IVIG)
Study: 23228814
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV)
Study: 18290777
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) monotherapy for 12 weeks
Study: 18290777
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ATRA and PegIFN‐alpha2a for 12 weeks
Study: 14614633
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (15 mg/kg/day) alone
Study: 14614633
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (15 mg/kg/day) plus low-dose aspirin (100 mg/day)
Study: 8368986
Drug: Benadryl (diphenhydramine)
Normalized name: diphenhydramine Oral Solution [Benadryl]
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benadryl (diphenhydramine) 50 mg
Study: 8368986
Drug: Hismanal (astemizole)
Normalized name: Astemizole
DrugBank: Astemizole (DB00637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hismanal (astemizole) 10 mg
Study: 30241517
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of amoxicillin dispersible tablets (DT) followed by 2 days of placebo DT
Study: 30241517
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of amoxicillin dispersible tablets (DT)
Study: 26603771
Drug: Methylprednisolone injection
Normalized name: methylprednisolone Injection
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone injection
Study: 24202666
Drug: wDP (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: wDP (docetaxel 35 mg/m² + cisplatin 60 mg/m²)
Study: 24202666
Drug: wDO (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: wDO (docetaxel 35 mg/m² + oxaliplatin 120 mg/m²)
Study: 23710844
Drug: email health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: email health information prescriptions (eHIP)
Study: 23710844
Drug: paper health
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: paper health information prescriptions (pHIP)
Study: 18500605
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine plus IV acetaminophen
Study: 15820798
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (minimal stimulation protocol)
Study: 10527011
Drug: No ICD
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ICD therapy (Control)
Study: 28049736
Drug: Liraglutide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (4 months treatment)
Study: 25856169
Drug: High-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caffeine (80 mg/kg i.v.)
Study: 25856169
Drug: Standard-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose caffeine (20 mg/kg i.v.)
Study: 23120958
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education at Kenyatta National Hospital (KNH)
Study: 18948162
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 300 mg once daily
Study: 18948162
Drug: quetiapine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine IR 150 mg twice daily
Study: 18948162
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 300 mg once daily and quetiapine IR 150 mg twice daily
Study: 17990061
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (1 mg or 2 mg)
Study: 17990061
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (1 mg or 2 mg) with motion stimulation
Study: 14512795
Drug: Paclitaxel monotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel monotherapy (100 mg/m2 intravenously on day 1 each week for 6 weeks)
Study: 14512795
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and carboplatin combination (Paclitaxel 80 mg/m2 intravenously followed by carboplatin 200 mg/m2 on day 1 each week for 6 weeks)
Study: 2249011
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy (C + R group)
Study: 27271517
Drug: Psychotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapeutic treatment recommendation implemented
Study: 17937798
Drug: Mental practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental practice embedded in daily therapy
Study: 11427271
Drug: QS-21/4 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: QS-21/4 mg/ml of polysorbate 80
Study: 11427271
Drug: QS-21/30 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: QS-21/30 mg/ml of hydroxypropyl-beta-cyclodextrin
Study: 11427271
Drug: QS-21/8-mg/ml of
Approvals — FDA: no, EMA: no, PMDA: no
Description: QS-21/8-mg/ml of polysorbate 80
Study: 26016866
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (GFJ) 340 mL/d providing 210 mg naringenin glycosides
Study: 23490394
Drug: Dynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic treatment (DT) for 24‐72 weeks based on viral decline rates
Study: 23490394
Drug: Dynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic treatment (DT)
Study: 23490394
Drug: Dynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic treatment (DT) among patients who achieved undetectable HCV RNA
Study: 21733046
Drug: Incentive of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive of 1 month of free treatment every fourth month of regularly respected visits (Group 2)
Study: 12924797
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (received intramuscular injection with purified trivalent split‐virus vaccine)
Study: 12924797
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (received intramuscular injection with vit B1)
Study: 12924797
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (mild COPD)
Study: 12924797
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (moderate COPD)
Study: 12924797
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (severe COPD)
Study: 12924797
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (all COPD patients)
Study: 12924797
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (patients with severe airflow obstruction)
Study: 8634222
Drug: Chlorpromazine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (administered over a 4-8 week period)
Study: 1962780
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin and vinblastine) followed by radiotherapy
Study: 6115521
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg metoprolol (acute beta 1-adrenergic blockade)
Study: 22796247
Drug: FF Rotadisk
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF Rotadisk 100 μg once daily in the morning
Study: 22796247
Drug: FF Rotadisk
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF Rotadisk 100 μg once daily in the evening
Study: 22796247
Drug: FF Rotadisk
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF Rotadisk 250 μg once daily in the evening
Study: 18558697
Drug: High Fructose
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Fructose Corn Syrup (HFCS)
Study: 16187917
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of octreotide-LAR every 4 weeks for 16 weeks
Study: 7585851
Drug: Roxatidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine (150 mg)
Study: 7384769
Drug: Glucose syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose syrup ingestion in the morning
Study: 28504033
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy (dexamethasone, cytarabine, cisplatin)
Study: 25844857
Drug: Short-wave diathermy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-wave diathermy (SWD) heat treatment for 40 minutes
Study: 10703777
Drug: IV tPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tPA therapy
Study: 8792483
Drug: 3-component DTaP
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-component DTaP vaccine
Study: 8792483
Drug: 2-component DTaP
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-component DTaP vaccine
Study: 6335343
Drug: Metoprolol group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol group (last metoprolol dose given 1.5 h before the anaesthesia)
Study: 6335343
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (last metoprolol dose 12 h before the anaesthesia)
Study: 26032211
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU of intranasal salmon calcitonin daily for 3 months
Study: 21804061
Drug: Lozenges containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenges containing anti-CA-gtf IgY
Study: 16650295
Drug: Allopurinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100 mg tds for 3 months) with ofloxacin (200 mg tds for 3 weeks)
Study: 16650295
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets with ofloxacin (200 mg tds for 3 weeks)
Study: 14647985
Drug: Sole injection
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole injection of NC into the lesion (group III)
Study: 14647985
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ROLL procedure with direct injection of MAA into the lesion and lymphoscintigraphy with subdermal injection of radiocolloids
Study: 11707007
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg/d cyclically for 14 days with 76-day intervals, plus calcium and vitamin D)
Study: 11707007
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/d daily)
Study: 1096666
Drug: Intravenous hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hyoscine butylbromide (Buscopan)
Study: 18373526
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg (titrated to 5 mg or 20 mg based on efficacy and safety)
Study: 16434427
Drug: Selective ET‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective ET‐A antagonist, BQ‐123 (n = 8) at 1000 and 3000 nmol/min
Study: 16434427
Drug: Selective ET‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective ET‐B antagonist, BQ‐788 (n = 8) at 100 and 300 nmol/min
Study: 12432293
Drug: Topical 0.3%
Normalized name: triclosan topical 0.3% topical bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.3% nifedipine and 1.5% lidocaine ointment every 12 hours for 6 weeks
Study: 12432293
Drug: Topical 1.5%
Normalized name: phenol topical 1.5% topical liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1.5% lidocaine and 1% hydrocortisone acetate ointment
Study: 7726809
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for social phobia (used for both refusers and excluded subjects)
Study: 7726809
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for social phobia (for acceptors)
Study: 2193461
Drug: Flutamide plus
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide plus leuprolide (LHRH-agonist)
Study: 2193461
Drug: Flutamide monotherapy
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide monotherapy
Study: 2193461
Drug: Flutamide in
Normalized name: Product containing flutamide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide in combination with LHRH-agonist
Study: 6432398
Drug: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS) 600 mg
Study: 6432398
Drug: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS) 800 mg
Study: 24675683
Drug: Dieting implementation
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dieting implementation intentions (e.g., If I open the fridge I will think of dieting!)
Study: 22269428
Drug: Enzastaurin plus
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin plus cisplatin-pemetrexed (125 or 250 mg twice daily)
Study: 17623381
Drug: Traditional ward
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional ward occupational therapy (WOT) programme (n = 37)
Study: 16041193
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam HCl and ezetimibe combination therapy
Study: 11993618
Drug: Glycerol loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol loading (1.2 g of glycerol per kg of body mass and 25 ml of a 0.75 g x kg(‐1) BM carbohydrate solution consumed over 60 minutes, 2 hours prior to ODT)